- Home
- ENSC vs UPXI Comparison
ENSC vs UPXI Comparison
Compare ENSC & UPXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- UPXI
- Stock Information
- Founded
- ENSC 2003
- UPXI 2018
- Country
- ENSC United States
- UPXI United States
- Employees
- ENSC N/A
- UPXI N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- UPXI Medicinal Chemicals and Botanical Products
- Sector
- ENSC Health Care
- UPXI Health Care
- Exchange
- ENSC Nasdaq
- UPXI Nasdaq
- Market Cap
- ENSC 5.5M
- UPXI 4.6M
- IPO Year
- ENSC N/A
- UPXI 2021
- Fundamental
- Price
- ENSC $2.64
- UPXI $2.20
- Analyst Decision
- ENSC
- UPXI
- Analyst Count
- ENSC 0
- UPXI 0
- Target Price
- ENSC N/A
- UPXI N/A
- AVG Volume (30 Days)
- ENSC 24.9K
- UPXI 13.2K
- Earning Date
- ENSC 05-12-2025
- UPXI 05-07-2025
- Dividend Yield
- ENSC N/A
- UPXI N/A
- EPS Growth
- ENSC N/A
- UPXI N/A
- EPS
- ENSC N/A
- UPXI N/A
- Revenue
- ENSC $5,210,031.00
- UPXI $18,625,089.00
- Revenue This Year
- ENSC N/A
- UPXI $299.03
- Revenue Next Year
- ENSC N/A
- UPXI N/A
- P/E Ratio
- ENSC N/A
- UPXI N/A
- Revenue Growth
- ENSC 133.58
- UPXI 4.75
- 52 Week Low
- ENSC $2.12
- UPXI $2.03
- 52 Week High
- ENSC $14.67
- UPXI $15.91
- Technical
- Relative Strength Index (RSI)
- ENSC 23.45
- UPXI 38.03
- Support Level
- ENSC $3.30
- UPXI $2.03
- Resistance Level
- ENSC $3.58
- UPXI $2.47
- Average True Range (ATR)
- ENSC 0.32
- UPXI 0.14
- MACD
- ENSC -0.05
- UPXI 0.01
- Stochastic Oscillator
- ENSC 22.21
- UPXI 30.09
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.